

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

Pursuant to the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, Sinopharm Group Co. Ltd. (the “**Company**”) is required to publish the quarterly financial information of the Company and its subsidiaries (the “**Group**”) which consists of consolidated balance sheet, consolidated income statement and consolidated cash flow statement of the Group, and to publish the quarterly financial information of the Company which consists of balance sheet, income statement and cash flow statement of the Company.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company is pleased to announce the unaudited financial information of the Group and of the Company for the nine months ended 30 September 2019 prepared in accordance with the PRC GAAP.

CONSOLIDATED FINANCIAL INFORMATION OF THE GROUP
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

Consolidated Balance Sheet of the Group as at 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2019	As at 31 December 2018
Current assets:		
Cash at bank and on hand	35,121,089,853.34	47,487,528,618.24
Financial assets held for trading	168,810.00	41,198,530.00
Notes receivables	1,594,863,721.24	4,257,138,963.27
Accounts receivables	142,715,762,934.24	96,601,274,662.65
Accounts receivable financing	6,495,466,843.12	5,565,180,501.19
Advances to suppliers	10,804,190,864.00	9,614,287,558.46
Other receivables	5,970,435,930.27	4,656,890,495.68
Inventories	45,478,266,553.45	35,003,521,705.93
Contract assets	256,660,236.28	250,294,490.79
Current portion of non-current assets	30,826,065.47	96,614,226.92
Other current assets	459,573,206.00	693,281,294.86
Total current assets	248,927,305,017.41	204,267,211,047.99
Non-current assets:		
Long-term receivables	1,901,719,978.98	1,928,460,253.20
Long-term equity investments	6,814,005,374.00	6,382,066,834.49
Equity investments designated at fair value through other comprehensive income	32,233,059.75	28,375,306.40
Other non-current financial assets	758,953,049.31	654,671,911.19
Investment properties	981,992,420.81	887,285,223.57
Fixed assets	8,371,817,920.45	8,018,091,594.45
Construction in progress	2,516,255,750.07	2,363,066,177.66
Right-of-use assets	4,286,746,419.12	-
Intangible assets	4,078,356,643.03	3,890,900,152.15
Development costs	60,336,477.57	50,046,687.35
Goodwill	5,505,532,804.40	4,850,729,292.44
Long-term prepaid expenses	870,249,623.73	767,864,418.15
Deferred tax assets	1,259,334,069.88	979,018,141.57
Other non-current assets	643,364,081.22	559,492,165.33
Total non-current assets	38,080,897,672.32	31,360,068,157.95
Total assets	287,008,202,689.73	235,627,279,205.94

Consolidated Balance Sheet of the Group as at 30 September 2019 (continued)

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2019	As at 31 December 2018
Current liabilities:		
Short-term borrowings	38,554,757,769.58	31,840,935,666.48
Notes payables	24,153,205,182.13	19,197,920,568.54
Accounts payables	80,097,884,386.10	64,485,006,710.90
Contract liabilities	7,094,777,531.60	6,101,607,127.18
Employee benefits payable	1,155,100,374.99	1,380,337,062.48
Taxes payable	1,694,301,060.64	2,061,429,077.23
Other payables	23,020,834,595.23	16,543,403,811.64
Current portion of non-current liabilities	1,525,917,558.85	4,471,456,225.19
Other current liabilities	21,014,012,886.95	13,993,421,372.39
Total current liabilities	198,310,791,346.07	160,075,517,622.03
Non-current liabilities:		
Long-term borrowings	574,000,000.00	657,310,000.00
Bonds payables	8,831,688,486.42	4,293,856,833.50
Lease liabilities	2,886,452,697.25	-
Long-term payables	508,809,793.89	208,139,938.58
Long-term employee benefits payable	84,064,165.89	95,537,599.89
Provisions	16,206,065.27	17,140,427.88
Deferred income	372,443,305.60	350,845,836.37
Deferred tax liabilities	856,473,031.12	864,905,946.02
Other non-current liabilities	625,709,266.32	613,268,601.09
Total non-current liabilities	14,755,846,811.76	7,101,005,183.33
Total liabilities	213,066,638,157.83	167,176,522,805.36

Consolidated Balance Sheet of the Group as at 30 September 2019 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2019	As at 31 December 2018
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	2,971,656,191.00	2,971,656,191.00
Capital surplus	17,174,503,191.67	17,050,886,595.55
Less: treasury shares held for share incentive scheme	135,317,558.39	135,317,558.39
Other comprehensive income	(7,213,992.37)	(3,288,793.12)
Specific reserve	1,090,863.31	1,145,336.11
Surplus reserve	1,071,084,654.97	1,071,084,654.97
Undistributed profits	24,824,430,373.41	21,982,464,277.25
Total shareholders' equity attributable to equity holders of the Company	45,900,233,723.60	42,938,630,703.37
Minority interest	28,041,330,808.30	25,512,125,697.21
Total owners' equity (or shareholders' equity)	73,941,564,531.90	68,450,756,400.58
Total liabilities and owners' equity (or shareholders' equity):	287,008,202,689.73	235,627,279,205.94

Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
1. Total operating revenue	312,688,146,247.71	250,820,438,349.45
Including: Operating revenue	312,688,146,247.71	250,820,438,349.45
2. Total operating cost	302,994,934,902.26	242,540,236,627.52
Including: Operating cost	285,463,843,093.20	228,242,219,276.03
Taxes and surcharges	688,495,855.06	574,038,331.74
Selling and distribution expenses	8,937,506,759.67	7,408,488,187.88
General and administrative expenses	4,379,505,398.67	3,398,823,671.10
Research and development expenses	96,783,993.67	74,654,536.67
Financial expenses	3,428,799,801.99	2,842,012,624.10
Add: Other gains (loss shall be stated as “-”)	231,162,384.32	193,386,289.87
Investment income (loss shall be stated as “-”)	656,217,825.82	542,179,514.68
Profit arising from changes in fair value (loss shall be stated as “-”)	3,639,841.58	41,197,530.49
Credit impairment losses (loss shall be stated as “-”)	(660,886,641.60)	(549,599,263.60)
Asset impairment losses (loss shall be stated as “-”)	(112,742,997.87)	(25,870,123.90)
Gains on disposal of assets (loss shall be stated as “-”)	2,984,655.14	4,386,845.89
3. Operating profit (loss shall be stated as “-”)	9,813,586,412.84	8,485,882,515.37
Add: Non-operating income	52,200,009.12	60,235,425.82
Less: Non-operating expenses	47,930,450.10	45,118,892.51
4. Total profit (total loss shall be stated as “-”)	9,817,855,971.86	8,500,999,048.68
Less: Income tax expenses	2,207,405,668.79	1,916,816,994.40
5. Net profit (net loss shall be stated as “-”)	7,610,450,303.07	6,584,182,054.28
Classification according to the continuity of operation		
Net profit from continuing operations	7,610,450,303.07	6,584,182,054.28
Net profit from discontinued operations	-	-
Attributable to:		
Net profit attributable to equity holders of the Company	4,595,243,248.85	4,117,328,353.52
Net profit attributable to minority interest	3,015,207,054.22	2,466,853,700.76
6. Other comprehensive income/(loss), net of tax	(2,621,457.62)	(15,385,096.25)
Net other comprehensive income/(loss) attributable to equity holders of the company	(3,925,199.25)	(13,432,596.14)
Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	800,189.24	(5,436,695.10)

**Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2019
(continued)**

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
Remeasurements of post-employment benefit obligations	(677,904.41)	-
Fair value losses on other equity instrument investments	1,478,093.65	(5,436,695.10)
<i>Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods</i>	(4,725,388.49)	(7,995,901.04)
Other comprehensive income/(loss) using the equity method that may be reclassified to profit or loss	391,268.17	(2,282,054.13)
Exchange differences on translation of foreign operations	(5,116,656.66)	(5,713,846.91)
Net profit/(loss) of other comprehensive income attributable to minority interest	1,303,741.63	(1,952,500.11)
7. Total comprehensive income	7,607,828,845.45	6,568,796,958.03
Total comprehensive income attributable to equity holders of the Company	4,591,318,049.60	4,103,895,757.38
Total comprehensive income attributable to minority interest	3,016,510,795.85	2,464,901,200.65
8. Earnings per share:		
Basic earnings per share	1.55	1.49
Diluted earnings per share	1.55	1.49

Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
1. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	320,172,856,309.92	256,711,933,157.34
Refund of taxes and surcharges	106,271,885.61	105,460,951.08
Cash received relating to other operating activities	3,919,445,223.01	2,882,277,669.42
Sub-total of cash inflows from operating activities	324,198,573,418.54	259,699,671,777.84
Cash paid for goods and services	317,434,587,320.64	256,225,403,061.46
Cash paid to and on behalf of employees	7,363,701,179.50	6,137,084,353.46
Payments of taxes and surcharges	7,537,649,455.23	6,210,668,682.02
Cash paid relating to other operating activities	7,427,531,547.52	5,150,908,141.03
Sub-total of cash outflows from operating activities	339,763,469,502.89	273,724,064,237.97
Net cash flows used in operating activities	(15,564,896,084.35)	(14,024,392,460.13)
2. Cash flows from investing activities:		
Cash received from disposal of investments	86,153,181.88	58,333,484.68
Cash received from returns on investments	213,150,827.76	268,708,805.44
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	100,962,150.17	61,541,381.76
Net cash received from disposal of subsidiaries and other business units	(1,472,447.32)	(1,394,218.48)
Cash received relating to other investing activities	26,740,274.22	-
Sub-total of cash inflows from investing activities	425,533,986.71	387,189,453.40
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,406,688,040.11	2,550,239,774.69
Cash paid to acquire investments	231,259,837.91	368,799,400.00
Net cash paid to acquire subsidiaries and other business units	663,545,837.51	280,577,428.51
Cash paid relating to other investing activities	849,882,333.84	608,342,361.68
Sub-total of cash outflows from investing activities	3,151,376,049.37	3,807,958,964.88
Net cash flows used in investing activities	(2,725,842,062.66)	(3,420,769,511.48)

Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2019 (continued)

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
3. Cash flows from financing activities:		
Cash received from capital contributions	800,667,517.00	612,613,632.00
Cash received from borrowings	73,150,363,093.59	68,161,449,787.61
Cash received relating to other financing activities	<u>1,196,797,279.64</u>	<u>4,787,189,118.58</u>
Sub-total of cash inflows from financing activities	<u>75,147,827,890.23</u>	<u>73,561,252,538.19</u>
Cash repayments of borrowings	62,689,632,933.62	50,749,845,891.22
Cash payments for interest expenses and distribution of dividends or profits	6,076,968,396.63	4,752,562,930.30
Cash payments relating to other financing activities	<u>1,372,795,288.82</u>	<u>5,790,528,474.97</u>
Sub-total of cash outflows from financing activities	<u>70,139,396,619.07</u>	<u>61,292,937,296.49</u>
Net cash flows from financing activities	<u>5,008,431,271.16</u>	<u>12,268,315,241.70</u>
4. Effect of foreign exchange rate changes on cash and cash equivalents	<u>5,985,777.11</u>	<u>(23,923,392.09)</u>
5. Net decrease in cash and cash equivalents	<u>(13,276,321,098.74)</u>	<u>(5,200,770,122.00)</u>
Add: Cash and cash equivalents at the beginning of the reporting period	40,298,985,123.85	32,249,947,148.88
6. Cash and cash equivalents at the end of the reporting period	<u>27,022,664,025.11</u>	<u>27,049,177,026.88</u>

FINANCIAL INFORMATION OF THE COMPANY
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

Balance Sheet of the Company as at 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2019	As at 31 December 2018
Current assets:		
Cash at bank and on hand	5,719,766,824.54	14,688,606,790.90
Notes receivables	59,462,324.02	50,970,458.62
Accounts receivables	3,066,347,886.29	1,999,942,234.96
Advances to suppliers	47,138,387.16	62,935,702.07
Other receivables	27,947,668,704.73	20,799,012,603.04
Inventories	912,375,974.39	814,944,833.12
Total current assets	37,752,760,101.13	38,416,412,622.71
Non-current assets:		
Long-term equity investments	30,882,198,549.30	30,156,315,186.29
Other non-current financial assets	597,409,092.96	598,377,954.84
Investment properties	23,940,351.35	24,688,738.70
Fixed assets	44,137,747.30	47,980,362.47
Construction in progress	1,909,739,158.92	1,891,580,663.18
Intangible assets	186,344,974.33	211,445,280.12
Long-term prepaid expenses	2,159,873.10	3,078,480.36
Deferred tax assets	72,516,958.67	75,521,975.61
Other non-current assets	90,147,632.72	60,880,747.55
Total non-current assets	33,808,594,338.65	33,069,869,389.12
Total assets	71,561,354,439.78	71,486,282,011.83

Balance Sheet of the Company as at 30 September 2019 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2019	As at 31 December 2018
Current liabilities:		
Short-term borrowings	-	900,000,000.00
Notes payables	474,949,173.39	669,011,736.52
Accounts payables	2,201,492,752.98	2,079,440,824.65
Contract liabilities	3,105,814.66	31,407,888.47
Employee benefits payable	46,599,933.49	45,752,322.41
Taxes payable	14,006,462.51	28,541,176.25
Other payables	12,462,214,112.59	18,506,583,343.96
Current portion of non-current liabilities	-	3,997,636,558.98
Other current liabilities	<u>20,491,132,642.91</u>	<u>13,992,337,000.89</u>
Total current liabilities	<u>35,693,500,892.53</u>	<u>40,250,710,852.13</u>
Non-current liabilities:		
Bonds payables	8,831,688,486.42	4,293,856,833.50
Deferred income	172,225.96	459,891.07
Deferred Tax Liabilities	22,796,546.27	23,241,371.27
Other non-current liabilities	<u>864,072,542.23</u>	<u>181,990,864.14</u>
Total non-current liabilities	<u>9,718,729,800.88</u>	<u>4,499,548,959.98</u>
Total liabilities	<u>45,412,230,693.41</u>	<u>44,750,259,812.11</u>

Balance Sheet of the Company as at 30 September 2019 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2019	As at 31 December 2018
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	2,971,656,191.00	2,971,656,191.00
Capital surplus	20,994,494,034.83	20,988,670,493.54
Less: treasury shares held for share incentive scheme	135,317,558.39	135,317,558.39
Other comprehensive income	5,088,075.47	5,863,991.89
Surplus reserve	1,072,928,171.82	1,072,928,171.82
Undistributed profits	<u>1,240,274,831.64</u>	<u>1,832,220,909.86</u>
Total owners' equity (or shareholders' equity)	<u>26,149,123,746.37</u>	<u>26,736,022,199.72</u>
Total liabilities and owners' equity (or shareholders' equity)	<u>71,561,354,439.78</u>	<u>71,486,282,011.83</u>

Income Statement of the Company for the Nine Months Ended 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
1. Total operating revenue	12,182,565,592.96	10,380,476,076.53
Including: Operating revenue	12,182,565,592.96	10,380,476,076.53
2. Total operating cost	12,251,129,947.07	10,462,860,360.36
Including: Operating cost	11,559,271,920.07	9,798,453,409.36
Taxes and surcharges	21,129,024.75	17,737,071.21
Selling and distribution expenses	187,318,166.03	144,286,377.17
General and administrative expenses	287,441,371.64	186,941,176.60
Research and development expenses	-	-
Financial expenses	195,969,464.58	315,442,326.02
Add: Other gains (loss shall be stated as “-”)	22,749,391.85	42,251,984.39
Investment income (loss shall be stated as “-”)	1,205,039,897.64	1,031,503,415.85
Profit arising from changes in fair value (loss shall be stated as “-”)	3,779,561.58	41,314,500.49
Credit impairment losses (loss shall be stated as “-”)	(10,425,755.06)	(11,370,619.85)
Asset impairment losses (loss shall be stated as “-”)	12,644,215.42	7,037,997.18
Gains on disposal of assets (loss shall be stated as “-”)	-	-
3. Operating profit (loss shall be stated as “-”)	1,165,222,957.32	1,028,352,994.23
Add: Non-operating income	203,547.09	28,673.76
Less: Non-operating expenses	145,064.45	2,574,630.91
4. Total profit (total loss shall be stated as “-”)	1,165,281,439.96	1,025,807,037.08
Less: Income tax expenses	3,950,365.49	4,455,516.03
5. Net profit (net loss shall be stated as “-”)	1,161,331,074.47	1,021,351,521.05
Classification according to the continuity of operation		
Net profit from continuing operations	1,161,331,074.47	1,021,351,521.05
Net profit from discontinued operations	-	-

Income Statement of the Company for the Nine Months Ended 30 September 2019 (continued)*(All amounts in RMB unless otherwise stated)*

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
6. Other comprehensive income/(loss), net of tax	(775,916.42)	(1,564,027.97)
<i>Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods</i>	-	-
<i>Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods</i>	(775,916.42)	(1,564,027.97)
Other comprehensive income using the equity method that may be reclassified to profit or loss	(775,916.42)	(1,564,027.97)
7. Total comprehensive income	1,160,555,158.05	1,019,787,493.08

Cash Flow Statement of the Company for the Nine Months Ended 30 September 2019

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
1. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	12,636,019,211.46	11,255,430,893.43
Refund of taxes and surcharges	-	41,459,118.88
Cash received relating to other operating activities	619,676,223.88	648,719,265.48
Sub-total of cash inflows from operating activities	13,255,695,435.34	11,945,609,277.79
Cash paid for goods and services	13,141,199,405.07	11,492,315,029.82
Cash paid to and on behalf of employees	212,571,500.38	224,219,871.59
Payments of taxes and surcharges	155,689,746.86	113,518,378.99
Cash paid relating to other operating activities	688,552,642.90	592,585,476.61
Sub-total of cash outflows from operating activities	14,198,013,295.21	12,422,638,757.01
Net cash flows used in operating activities	(942,317,859.87)	(477,029,479.22)
2. Cash flows from investing activities:		
Cash received from disposal of investments	65,453,503.88	58,333,485.68
Cash received from returns on investments	1,019,279,987.76	1,038,268,309.12
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	-	44,775.60
Net cash received from disposal of subsidiaries and other business units	(1,472,447.32)	-
Cash received relating to other investing activities	2,121,953,511.88	637,142,899.78
Sub-total of cash inflows from investing activities	3,205,214,556.20	1,733,789,470.18
Cash paid to acquire fixed assets, intangible assets and other long-term assets	41,342,820.51	1,341,851,645.94
Cash paid to acquire investments	693,162,622.40	1,223,942,400.00
Cash paid relating to other investing activities	8,069,140,963.44	7,627,225,524.56
Sub-total of cash outflows from investing activities	8,803,646,406.35	10,193,019,570.50
Net cash flows used in investing activities	(5,598,431,850.15)	(8,459,230,100.32)

Cash Flow Statement of the Company for the Nine Months Ended 30 September 2019
(continued)

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2019	For the nine months ended 30 September 2018
3. Cash flows from financing activities:		
Cash received from borrowings	28,773,134,783.19	27,679,365,800.00
Cash received relating to other financing activities	<u>210,692,714,773.14</u>	<u>165,889,989,156.53</u>
Sub-total of cash inflows from financing activities	<u>239,465,849,556.33</u>	<u>193,569,354,956.53</u>
Cash repayments of borrowings	22,665,355,483.19	17,529,990,011.50
Cash payments for interest expenses and distribution of dividends or profits	2,279,444,693.88	2,268,608,027.15
Cash payments relating to other financing activities	<u>216,950,174,850.13</u>	<u>169,442,678,495.71</u>
Sub-total of cash outflows from financing activities	<u>241,894,975,027.20</u>	<u>189,241,276,534.36</u>
Net cash flows (used in)/from financing activities	<u>(2,429,125,470.87)</u>	<u>4,328,078,422.17</u>
4. Effect of foreign exchange rate changes on cash and cash equivalents	1,035,214.53	1,791,989.90
5. Net decrease in cash and cash equivalents	<u>(8,968,839,966.36)</u>	<u>(4,606,389,167.47)</u>
Add: Cash and cash equivalents at the beginning of the reporting period	<u>14,688,606,790.90</u>	<u>9,680,575,167.32</u>
6. Cash and cash equivalents at the end of the reporting period	<u>5,719,766,824.54</u>	<u>5,074,185,999.85</u>

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
25 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Dai Kun; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*